BIOINVEST BREAKING NEWS – Ionis (IONS) IONS and their partner AZN are both down on negative trial results from CARDIO-TTRansform. The trial failed to meet its primary endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events in ATTR-CM patients through Week-140. (…more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.